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1. Introduction 
 
Pancreatic cancer is the fourth leading cause of cancer related deaths in both men and women in 
United States.[1] In 2017, it is estimated that 53670 Americans will be diagnosed and 43090 
patients will die of pancreatic cancer [2]. Most patients get diagnosed with pancreatic ductal 
adenocarcinoma and the 5-year survival rate after surgical resection is 20% and for those with 
metastatic disease, the survival rate is 2%[3]. Late detection and diagnosis has been the critical 
reason for poor survival rate in pancreatic cancer patients, 85% of patients present with advanced 
disease that is unresectable.[1] 
 
 
 
 
African Americans have appreciably higher rates than whites. Heritable, germline mutations in 
p16, BRCA2[4], and other genes appear to be associated with a total of 5%–10% of all 
pancreatic cancers, and penetrance of these mutations for the disease may be fairly low. Chronic 
pancreatitis of various types is associated with another 3%–4%. Apart from germline mutations  
or pancreatitis, the other major risk factor associated with pancreatic cancer is cigarette smoking. 
Past studies suggest that patients with pancreatic cancer who smoked cigarettes were 
approximately at 40% increased hazard for death compared with those who never smoked, and 
risk tends to increase according to the frequency or duration of smoking[5]. Dietary studies have 
shown a fairly steady pattern of increase hazard with meat or cholesterol intake and decreased 
risk with fruit or vegetable consumption, although causal inferences regarding these associations 
are still uncertain [6]. 
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Fig 1. Incidence of pancreatic cancer[7] 
 
Pancreatic cancer rates in US by sex, race and ethnicity. In all the group blacks have higher 
incidence rate of pancreatic cancer. According to sex, men have higher incidence rate than 
women. 
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Fig 2. Pancreatic cancer mortality rates and incidence among men and women, by regions, GLOBOCAN 
2012 estimates.[7] 
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2.1 Environmental agent affecting pancreatic cancer 
 
In spite of decades of research, the etiology of pancreatic cancer still remains ambiguous [8]. 
The cause of cancer is complex web of multiple factors[9]. Environment, lifestyle, diet, viral 
agents, genetics, and occupational exposures all can contribute to pathogenesis of tumor. 
Cancer causation is extraordinarily intricate. The agents and mechanism which contributes to 
pancreatic cancer are still not known. One of the major risk factor associated with pancreatic 
cancer is tobacco smoking, which contributes to one third of cases [10]. A personal history of 
chronic pancreatitis, diabetes, and high body-mass index, as well as family history of cancer has 
higher incidence rate of causing pancreatic cancer [11]. 
Earlier studies indicate that people who are occupationally exposed to various chemicals and 
metals such as benzidene and β-napthylamine, pesticides, asbestos, benzene, chlorinated 
hydrocarbons, chromium, and nickel [12, 13] tend to have higher risk of pancreatic cancer. The 
mechanism by which such exposures may lead to pancreatic cancer is still ambiguous. It is 
assumed that these substances through bloodstream may reach the pancreas and in this 
process, tumor suppressor proteins get inactivated, exert genotoxic effects leading to altered 
methylation and formation of DNA adducts [14, 15]. 
A meta-analysis of work related to occupational exposures and incidence of pancreatic cancer 
covering 92 studies [12, 16] reported that workers who were occupationally exposed to nickel 
and chlorinated hydrocarbon solvents tend to have higher risk of pancreatic cancer, as well as 
to other substances including chromium and organochlorine pesticides showed marked 
increase in risk to pancreatic cancer. Several work related to occupational studies have linked 
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carcinogenic substances like chromium, chlorinated hydrocarbons, nickel to pancreas 
carcinogenesis [17, 18]. Farmers who are highly exposed to pesticides have also been reported 
to show increased risk of pancreatic cancer [16, 19-21] although not consistent [16, 22, 23]. 
Studies relating to asbestos and benzene exposure leading to pancreatic cancer are subtle and 
ambiguous. [12, 13, 24] .Epidemiologic data suggest that although the incidence of pancreatic 
cancer is low in Japan compared with that of United States, Japanese who have immigrated to  
the United States have a increased risk than that of the native white population of this 
country.[25] 
 
One of the major risk factor associated with pancreatic cancer is cigarette smoking which 
contributes to nearly 20% of pancreatic cancer cases [26, 27]. In a study of 12 prospective 
cohorts and one case-control study, people who smoked cigarettes had 80% increased risk of 
pancreatic cancer compared with non-smokers, and the risk increased with smoking duration, 
intensity, and cumulative smoking dose [28]. Nevertheless, few studies have examined survival 
probability who smoked cigarette and among patients with pancreatic cancer. There is a 
significant association in reduction in survival among patients who smoked cigarette and had 
pancreatic cancer. Furthermore, reduction in patient survival was observed with high levels of 
plasma cotinine, the major circulating metabolite of nicotine.[27] 
 
In recent years there have been numerous case control studies to determine whether coffee or 
alcohol effects pancreatic cancer risk [14, 29]. The results obtained till now are fairly 
inconsistent. Many attributes may contribute to these inconsistent results. Poor survival rate leads 
to  reduce  participation  rate  in  clinical  studies.  Moreover,  in  population-based   case-control 
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studies, heavy alcohol and coffee drinkers may have lower participation rates than nondrinkers 
[30]. Thus, environmental factors appear to play a vital role in the etiology of pancreatic cancer. 
 
2.2 Prognosis: Pancreatic cancer 
 
Pancreatic cancer (PC) is a devastating disease and the fourth, fifth and seventh leading cause of 
cancer-related death in  the  United  States,  European  Union  and  China,  respectively  [31-  
33]. Large population-based studies in western countries indicated an overall  5-year survival  
rate less than 5% and a median survival of 3–6 months [34-36]. The median survival rate was 4 
months and the 2-year survival rate increased from 4.6% in 1988 to 7.7% in 2000 according to 
the Surveillance, Epidemiology, and End Results Registry(SEER) from 1988 through 2002 [34]. 
 
A post resection prognosis study indicates that edian survival times in pancreatic cancer patients 
after R0 resection are between 17 and 28 months whereas after R1/R2 resection the median 
survival is between 8 and 22 months [37-41]. The survival probability by Kaplan Meier analysis 
after R0 resection indicates a 5-, 3-, and 1- year survival of 20%, 35%, and 80% respectively [42- 
45]. Less than 2% of people survived, in a long-term follow-up as the basis for estimating the 
prognosis [46, 47]. The identifying symptoms of local relapse are loco regional microscopic 
tumor cell residues, recurrence of pain due to the cancer infiltrating the nerves, and lymph node 
metastases [48]. This phenomenon is very common and escapes CT diagnosis if there is no 
substantial tumor formed. The most common cause of pancreatic cancer death is due to 
progressive organ metastasis and not the local relapse. 
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Fig 3. Five-year survival rate at diagnosis 
 
Most pancreatic cancer patients get diagnosed when cancer has metastasized to other parts and 
five year survival rate is less than 3% [2] 
 
 
Fig 4. Percent of pancreatic cancer cases by stage at diagnosis. 
 
Cancer stage at diagnosis. Cancer stage has strong correlation to length of pancreatic cancer 
patient survival and also determines treatment options [2]. 
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Fig 5. Percent of new pancreatic cancer cases by age group. 
 
Pancreatic cancer incidence rate is slightly high in men than women and most frequently 
diagnosed among age 65-74 [2]. 
 
 
 
2.4 Mdig in cancer 
 
The mineral dust-induced gene (mdig) was first identified from alveolar macrophages obtained 
from people with chronic lung disease resulting from occupational to mineral dust [49]. This 
gene was independently characterized in human glioblastoma cell lines with an over expression 
of c-myc oncogene and named as myc-induced nuclear antigen 53 (mina53)[50] or nucleolar 
protein 52 (NO5) [51]. The location human mdig/MINA gene is on chromosome 3 (3q12.1) that 
encodes a protein that weights 53 kDa. The protein is mainly localized in the nucleus, although 
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some of them are expressed in the nucleolus. Mdig can be induced by a number of environmental 
hazards, such as arsenic, silica, coal dust, and particulate matter PM 2.5[52]. The mdig gene 
encodes a 53 kDa protein that is involved in cell proliferation, neoplastic transformation, 
epigenetics, and immune regulation, and is over expressed in a variety of human neoplasms [52]. 
The mdig encodes a protein with a conserved JmjC domain and is indicated in cell growth 
 
regulation, possibly through its effect on tri-methylation of lysine 9 on histone H3 (H3K9me3) 
 
and hydroxylase activity on ribosomal proteins[53]. 
 
Mdig/MINA protein has four isoforms produced due to alternative splicing. Isoform 1 has been 
chosen as the ‘canonical’ sequence. Isoform 2 with a mass of 31.8 kDa , isoform 3 with a mass  
of 23.9 kDa and isoform 4 with a mass of 52.6 kDa has been reported in the literature. Mdig 
belongs to the JmjC family of proteins with one JmjC domain. JmjC domain functions by histone 
demethylation mechanism. Proteins containing JmjC domain are mainly involved in the 
regulation of chromatin remodeling and are predicted to be metallo-enzymes adopting the cupin 
fold. Electro-spray ionization-mass spectrometry guided disulphide cross-linking technology are 
used to identify the substrate complexes for mdig/MINA. MINA (Tyrosine 209C) residue readily 
cross-links and crystallizes in complex with RPL27A (G37C). 
 
 
 
 
 
Fig 6. Position of Jmjc domain (purple background) in mdig protein [53] 
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Fig 7. Expression of mdig in different human tissues [53] 
 
2.3 Alternative splicing in cancer 
 
In human 92%-94% of genes undergo alternative splicing which results in proteome diversity 
[54]. In this process introns are removed from the nascent RNA and joins to exon to form mature 
RNA, which ultimately get translated into proteins [55]. Spliceosome acts as a catalyst for 
removal of introns, which assembles at the borders between introns and exons, called as ‘splice 
junctions’. Rearrangement of exons may take place, skipping of some parts; mutual exclusion or 
inclusion of intron resulting in mature RNA [56]. These processes are collectively termed as 
Alternative Splicing. This further translates into protein which is highly diverse and complex, 
Alternative splicing results in extensive variety in cell function due to amplification of protein 
interactions and signaling. 
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2.3.1 Alternative splicing of mdig mRNA in lung cancer cell line. 
 
 
 
In our earlier studies alternative spliced transcripts of mdig mRNA was found in lung cancer cell 
lines [49]. The presence of alternative spliced mRNA has shown implication in different cancer 
types due to aberrant splicing and abnormal protein production [57]. During this process introns 
are removed from the nascent RNA and joins to exon to form mature RNA, which ultimately get 
translated into proteins. The alternative splice variants of mdig mRNA was produced as 
consequence of alternative promoters or alternative splice mRNA involvement. To characterize 
the nature of alternative splice mdig in H441 cells, amplification of RT-PCR primer sets I and III 
was purified and sequenced [49]. After DNA sequencing and analysis of data it was found that,  
in mdig2 (GenBank Access number: AY456380) the entire region of exon 2 (471 bp) was  absent 
but contains a 207 bp region that illustrate a new alternative exon inserted between exon 5 and 
exon 6 . JmjC homology domain is absent in new protein. Schematic representations of exon of 
mdig mRNA in A549 and H441 cells is shown in figure [49]. 
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Fig 8. Alternative splicing of mdig mRNA in lung cancer cell line. 
 
 
(a) Schematic  representation  of  RT−PCR  primers  in  correlation   to   their   exons   in   
the mdig gene. (b) Expression level of mdig mRNA in A549 cells (left) and H441 cells 
(right).   (c)   DNA   sequencing   of   primer   extension   demonstrated   a   new    region 
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of mdig mRNA in H441 cells, due to use of an alternative exon (5') with a size of 207 bp 
[49]. 
 
 
In cancer, the process of splicing is mainly disrupted leading to both functional and non- 
functional end-products [58]. In recent years, alternative splicing specific to Cancer contributing 
to disease progression and its pathological implications have been well described however, the 
deregulation pattern due to alternative splicing found on a genome-wide scale have not yet fully 
elucidated [59-62]. It’s important to understand molecular mechanisms which determine the 
choice of particular splicing events associated with these processes, which will eventually help in 
interpreting how normal development occurs and how cancers progresses and metastasize. 
 
A research study carried by Hanahan and Weinberg in 2000 which describes about tumor growth 
and development, tumor obtains additional oncogenic properties as cell progress through various 
processes [63]. And also mentions about eight processes required for development of tumor and 
progression to metastases [64]. Important attribute for tumor growth is unlimited proliferation of 
cells, but other processes such as growth factor, self sufficiency, immune escape, and invasion 
and antiapoptotic mechanisms are also vital properties acquired by tumors which eventually 
progress to form threatening malignancies. It’s now possible to understand this mechanism with 
the help of high-throughput proteomic and genomic techniques which allows identifying the 
mutations in oncogene for each cancer type [56]. As increasing number of cancer study taking 
places, a clear co-ordination of hallmarks of cancer is being put together. 
 
Aberrant splicing is widely seen in most types of cancer [59]. Functions of aberrant splicing 
events in healthy tissues is not known [65] whereas in cancer related genes functional diversity is 
a result of alternative splicing[66]. 
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2.3.2 Aberrant splicing effecting hallmarks of cancer 
 
Aberrant splicing is known to affect widely accepted hallmarks of cancer [56, 64]. Alternative 
splicing of genes affects the apoptosis and metastasis. Aberrant splicing induced  angiogenesis 
are one of the best described events in cancer. Mainly, a splicing switch is observed between 
cancer and healthy tissue samples of pro and anti-angiogenic isoforms of VEGFA [67]. 
Resistance to apoptosis is shown to confer with the up regulation of anti-apoptotic transcript 
variants of BCLXL [68, 69]. Furthermore, CD44 is involved in metastasis with more than 20 
alternative splicing events [59]. 
 
 
Many alternatively spliced genes are involved in regulation of more than one cancer hallmark. 
One such example is RAC1B isoforms which is involved in inflammation and genomic  
instability by increasing the cellular levels reactive oxygen species due to increase cell invasion 
and proliferation potential of cancer cells [70-73]. Splicing of TP53 isoforms is implicated in  
both apoptosis and cell proliferation [74]. Further, expression of BRAF proto-oncogene is known 
to affect its kinase domain [75]. As aberrant splicing is involved in number of stages in cancer 
development, as a result many research studies have claimed aberrant splicing itself is a hallmark 
of cancer [58, 61, 65, 66, 76-79]. 
15 
 
 
 
 
 
 
Fig 9. Cancer hallmark and alternative splicing. 
Alternative splicing of genes involved in development of cancer (blue background). Some genes 
(orange background) are involved in several events in cancer development [76, 79-88]. 
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2.5 Progression model for pancreatic adenocarcinoma 
 
 
 
 
 
 
 
 
 
 
 
Fig 10. 
 
Progression model for pancreatic adeocarcinoma. 
 
Stage wise development of pancreatic ductal cells to infiltrating cancer. In the initial stages, 
mutation of K-ras gene occurs, p16 gene inactivates at an intermediate stage, inactivation of p53, 
DPC4 and BRCA2 occur relatively late [89, 90]. 
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Earlier studies suggest that pancreatic cancer develops in a step-wise progression. Histologic and 
genetic alterations occur in parallel series which leads to invasive PDAC [89, 91]. The 
standardized pathologic classification system describes an increasing degree of cytologic and 
architectural atypia from PanIN-1 (lowest grade)  to  PanIN-3  (highest  grade)  lesions[92]. In  
the K-ras oncogene, duct lesions with minimal cytologic and architectural atypia also have been 
shown to have point mutations. In pancreatic carcinogenesis K-ras mutation occurs in early 
stage[93]. P16 inactivation is an intermediate event and inactivations of p53 and DPC4 appear to 
be late events in this progression model.[1, 94] 
 
 
 
 
 
2.6 Oncogene and tumor suppressor genes altered in PDAC 
 
K-ras in PDAC, studies of resected tumors suggest that this mutation is present in nearly all 
cases[95]. In  the pathogenesis of PDAC, K-ras mutation is indeed believed to occur in early  
stage [92]. K-ras gene is located on chromosome 12 which encodes a member of the Ras family 
of GTP-binding proteins that transduces cellular growth, differentiation, and survival signals[96]. 
 
In pancreatic carcinoma, 95% of p16 tumor suppressor gets inactivated [97]. P16 is located on 
chromosome 9, where it encodes a protein that inhibits entry into the S phase of the cell cycle by 
inhibiting cyclin-dependent kinase (CDK) 4/6-dependent phosphorylation of retinoblastoma (RB) 
protein. p16 inactivation leads to unregulated cell growth by inappropriate progression through 
the cell cycle[98]. Inactivation of p16 mechanism leads to intragenic mutation plus loss of 
heterozygosity (LOH), promoter hypermethylation and homozygous deletion. 
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In addition to p16 inactivation, about 50% to75% of pancreatic cancer show dysfunction 
of p53, one of the most important tumor suppressors [99]. As a transcription factor whose gene  
is located on 17 chromosomes, p53 regulates a variety of signaling pathways linked to cell cycle 
arrest, apoptosis, and DNA repair. Accordingly, functional inhibition of p53 will lead to loss of 
cell cycle “check-point” [98, 100]. 
 
 
2.7 Signal transduction pathways in PDAC 
 
Mitogen-Activated Protein Kinase (MAPK) Cascade activating K-ras mutations and growth 
factor receptor (eg, EGFR)-ligand interactions are relevant to activation of this cascade in 
pancreatic cancer. Ras activation results in activation of serine/threonine kinases  which 
ultimately activates downstream effector extracellular signal-related kinase (ERK). ERK- 
mediated phosphorylation of its substrates assist cell proliferation, survival, and differentiation 
[101]. Activation of this pathway results in increased survival, growth and invasion of pancreatic 
cancer cells [102]. 
 
Ras and other growth factor-activated tyrosine kinase has shown implication in activation of 
Mammalian Target of Rapamycin (mTOR)/Phosphoinositide 3-Kinase (PI3K)/AKT/ Signaling 
Cascade [101]. Activation of this pathway culminate to overexpression in PDAC and cell 
mediated proliferation, chemo resistance and survival. [102]. 
 
Constitutive activation of Nuclear Factor Kappa B (NF-κB) Signaling Cascade is studied in 
nearly all pancreatic cancer cell lines and PDAC tissues[103]. NF-κB–regulated genes assist in 
angiogenesis, chemo resistance, cell survival and invasion [102]. Due to the number of signaling 
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pathways leading to PDAC, pathogenesis of this disease have become complicated which 
ultimately leads to poor survival of pancreatic cancer patients.[104] 
 
In the present study, we evaluated the expression of mdig in pancreatic adenocarcinoma 
cell lines at protein and mRNA levels. Using immunohistochemistry (IHC) approach, we  
detected expression of mdig in human pancreatic cancer tissues and assessed its association with 
clinicopathological features and prognosis. We showed that about 12% and 38% of total 
pancreatic malignant tissue were found to be strongly and moderately positive for mdig. We also 
demonstrated the presence of the alternatively spliced mdig mRNAs in pancreatic cancer cell 
lines we tested. Through R2: Genomics Analysis, we found opposite predictive power of 
different exon regions for the survival of the pancreatic cancer patients, which possibly  
suggested diversified roles of the alternatively spliced mdig mRNAs in the pathogenesis and 
prognosis of the pancreatic cancer. 
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2. Materials and methods 
 
 
 
Cell culture 
 
The human pancreatic adenocarcinoma (PA) cell line Bxpc3, Aspc1 and MIAPaca2 were 
purchased from the American Type Culture Collection (ATCC, Manassas, VA). Aspc1 and 
MIAPaca2 cells were cultured in Dulbecco's Modified Eagle's Medium - high glucose (DMEM) 
with 10% fetal bovine serum (Invitrogen), 1% penicillin–streptomycin .Bxpc3 cells  were  
cultured in RPMI-1640 medium (HyClone) with 10% fetal bovine serum and 1% penicillin– 
streptomycin and in presence of 5% CO2. Arsenic chloride (As3+, Sigma-Aldrich,  MO) was  used  in 1,  
5, 10µM 
Western blotting 
 
 
Total cellular proteins were prepared by lysing the cells in RIPA buffer (Millipore, Billerica, MA) 
supplemented with phosphatase/protease inhibitor cocktail and 1 mM PMSF through sonication 
and centrifugation, followed by quantification using a Micro BCA Protein Assay Reagent Kit 
(Thermo Scientific, Pittsburgh, PA). Before loading on 10% SDS-PAGE gels, the proteins were 
boiled in LDS sample buffer (Invitrogen) containing 1 mM dithiothreitol. The proteins were 
separated and transferred onto PVDF membranes (Invitrogen). Membranes were probed with the 
primary antibody at a dilution of 1:1000 or 1:2000(according to signal intensity) overnight at 4C. 
The secondary antibody with HRP was applied at the dilution of 1:2000. The mdig antibody was 
purchased from Ivitrogen and GAPDH was purchased from Cell Signaling Technology, Inc. 
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RT-PCR 
 
Total RNA was prepared by lysing the cells with TRIzol reagent (Invitrogen). Access Quick RT- 
PCR System (Promega) was used for reverse transcription and PCR. Sample composed of 1 μg  
of total RNA and 0.3 μM sense and anti-sense primer. The primer sequences for mdig are: left 
primer: 5′-TCATGTCGGGCCTAAGAGAC-3′; right primer:  5′- 
GGCATTTGATTCTGCAAAGG-3′, which amplify a 1509 bp cDNA fragment covering the 
entire coding region of the mdig mRNA. The primer sequences for GAPDH are: sense: 5′- 
CTGAACGGGAAGCTCACTGGCATGGCCT-3′;   antisense: 
5′CATGAGGTCCACCACCCTGTTGCTGTAG-3′. 
Immunohistochemistry 
 
The tissue microarray slide BC14012 was purchased from US Biomax, Inc. (Rockville, MD) and 
deparaffinization was performed using Xylene and was hydrated in series of alcohol. Slides were 
incubated with 1.5% H2O2 for 20 min at room temperature, to quench the endogenous peroxidase 
activity. Non-specific binding of immunoglobulin was blocked by incubating slides in a solution 
consisting of 5% goat serum and 0.2% triton-X 100 in PBS for 2 h at room temperature. Then the 
slides were incubated with monoclonal antibody against Mdig (mouse anti-Mina 53, Invitrogen) 
in 1:100 dilutions at 4 °C overnight. Proceeding day goat anti-mouse secondary antibody was 
applied at 1:200 dilution and incubated at room temperature for 2 h. Followed by incubation with 
an ABC reagent (Vectastain Elite ABC kit) at room temperature for 45 min and the chromogen 
was developed with diaminobenzidine (DAB). Hematoxylin was used as counterstain and it was 
mounted with entellan. All incubation steps were carried out in a humidified chamber and all 
washing steps were performed with 1 × PBS. Bright field optics of the Nikon Eclipse Ti-S 
Inverted microscope (Mager Scientific, Dexter MI, USA) was used to capture the images. 
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Migration and Invasion assay 
 
 
Cell migration and invasion were determined using BD BioCoat™ Matrigel™ Invasion and 
Migration Chambers according to the manufacturer's instruction. After incubating for 24 h, the 
cells in the upper chambers were scrubbed out using cotton tipped swab. Diff-Quik staining was 
performed on the lower surface of the membrane. The migrated and invasive cells were counted 
under a microscope. 
 
 
 
 
Cell viability assay 
 
 
For cell viability assay 1×10
5 
cells/well were seeded in 24 well plates (Corning Inc., Corning, 
NY, USA). After 24 hours the cells were treated with 1, 5 and 10µM arsenic (As3
+) 
in triplicate. 
After 24hours of treatment the medium was aspirated and 0.5% para formaldehyde was used for 
10 minutes to fix the cells. The cells were washed twice in gentle stream of water. For staining 
200µl 0.5% crystal violet was added in each well. The optical density (OD) of treated cells was 
determined at a wavelength of 450nm with a micro plate reader. 
 
Survival analysis and statistics 
 
 
The measurement errors for quantitative experiments were determined using standard deviation 
(SD). Comparison between mdig expression and clinicopathologic variables were determined by 
chi-square test. P value of ≤ 0.05 were considered statistically significant. Data were analyzed 
using IBM SPSS Statistics 22.0 (SPSS, Chicago, IL, USA). R2: Genomics Analysis and 
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Visualization Platform (http://r2.amc.nl) a public data set was used to analyses Kaplan meier 
 
survival curve. 
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3. Results 
 
 
4.1 Expression of Mdig in Human Pancreatic Adenocarcinoma Cell Lines. 
 
 
An over expression of mdig has been observed in a number of human cancers, implying its 
important role in the pathogenesis of human malignancies. To investigate whether mdig is over 
expressed in pancreatic cancer, the level of mdig expression was determined by western blot 
technique (Fig 11). In three pancreatic cancer cell lines, Bxpc3, Aspc1 and MIAPaca2, we found 
that mdig protein was detected in these cell lines cultured in either presence or absence of serum. 
Several repeating experiments suggested that relative to other two cell lines, the AsPc1 cells 
expressed lower level of mdig protein. 
 
 
 
 
 
 
 
Fig 11. Expression of mdig in human pancreatic cancer cell lines. The indicated cells were 
cultured in the medium with or without 5% of serum for 24 hours. Total cell lysates were used 
for Westernblotting using antibodies against mdig and GAPDH. Two representative results were 
shown. 
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4.2 Pancreatic Adenocarcinoma Cell lines Express Alternatively Spliced Mdig mRNAs. 
 
In an effort to determine the mRNA levels of mdig among these pancreatic cancer cell lines, a 
traditional RT-PCR was applied for the detection of mdig mRNAs. The PCR primer set was 
derived from exon 1 and exon 10 regions of mdig gene, respectively, which amplifies a 1,510 bp 
fragment of mdig mRNA encompassing the entire open reading frame. A marginal increased 
expression of the full length mdig mRNA was noted among these cell lines cultured in the 
serum-free medium (Fig. 12). We had previously reported that there are alternatively spliced 
mdig mRNAs in which the entire exon 2 region was spliced out with or without inclusion of an 
alternative exon 5’ in lung epithelial cells and lung cancer cells. Such alternatively spliced mdig 
mRNAs with sizes around 500 to 650 bp were detected in all of these pancreatic cancer cell lines 
(Fig. 12). In contrast to the full length 1,510 bp mdig mRNA, the expression level of the 
alternatively spliced mdig mRNAs was decreased in the cells cultured in serum-free medium, 
suggesting different regulatory mechanisms for the expression of the full length and alternatively 
spliced mdig mRNAs. 
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Fig 12. Expression and Alternative Splicing of mdig mRNA in Pancreatic Cancer Cell Line. 
 
Total RNAs were the cells cultured in the conditions as described in Fig. 1.  RT-PCR was 
 
performed using the primer set that amplifies full length mdig mRNA with a size of 1,510bp. 
 
The PCR products were separated on 1% agarose gel.  Arrows indicates full length and the 
 
alternatively spliced mdig mRNAs. 
 
4.3 Correlation of Mdig Expression and the Pathogenesis of Pancreatic Cancer. 
 
We and others had demonstrated an association of mdig expression and the pathogenesis 
of lung cancer, breast cancer and other cancers. To determine whether there is a correlation 
between mdig expression and the clinical characteristics of the human pancreatic cancer, we 
measured the protein level of mdig among the pancreatic tissues through immunohistochemistry 
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on a tissue microarray containing 42 cases of pancreatic cancer tissues and 6 normal pancreatic 
tissues. Based on the staining intensities of mdig, we found that in the normal pancreatic tissues 
34% was moderately positive and 66% was weakly positive, no strongly positive staining of  
mdig was detected (Fig 13a). However, in the pancreatic malignant tissue, we found 12% strong 
positive, 39% moderately positive, 31% weakly positive and 18% negative (Fig 13b). 
28 
 
 
 
 
 
 
 
 
Fig 13. Immunohistochemical Analysis of Mdig Protein in the Human Pancreatic Tissue 
and Pancreatic Adenocarcinoma Tissue Microarray. 
Paraffin embedded tissue microarray slide was immunostained for mdig protein as described in 
Materials and Methods. Red arrows depict the cells positive for mdig. Scale = 50 M; 
Magnification = 40X A. Normal pancreatic tissues; B. Pancreatic adenocarcinoma. 
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Fig 14. Quantification of mdig expression in Pancreas malignant adenocarcinoma and 
normal pancreatic tissue 
 
 
 
4.4 Correlations between Mdig Expression and Clinicopathological Features in Pancreatic 
Cancer Patients 
To further evaluate mdig expression and the pathogenesis of pancreatic cancer tissues, we 
determined the protein levels of mdig by IHC analysis among the pancreatic cancer tissues with 
well-defined clinicopathological features. The association between mdig expression and 
clinicopathological  variables  in  pancreatic  cancer  patients  was  analyzed  additionally by chi- 
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square test (Table 1). Among these variables, we found that cancer grades 2 and 3 exhibited a 
significantly strong mdig expression than the pancreatic cancer tissues at grade 1 (p = 0.03) (Fig 
4). No other clinicopathological variables showed a significant correlation with mdig expression. 
 
 
 
Variables 
 
 
No. 
Mdig expression  
 
P-value Low No. (%) High No. (%) 
Gender    0.695 
Male 12 6 6  
Female 30 13 17  
Age(years)    0.118 
>60 30 12 18  
<60 12 8 4  
Cancer grade    0.034 
1 19 12 7  
2&3 23 7 16  
 
Table 1. Expression levels of mdig and the clinicopathological variables of the pancreatic 
cancer patients. Pearson chi-square tests was performed to determine the p-value 
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Fig 15. Quantification of Mdig expression in pancreatic adenocarcinoma tissues at different 
stages. 
 
 
 
 
 
4.5 Increased Invasion and Migration in Pancreatic Cancer Cell Lines 
 
 
Cell invasion and migration is important component in the spread of pancreatic cancer. In the 
early stage of disease, cancer spread is thought to occur after tumor cells infiltrate the peritoneal 
activity and gain access to blood vessels. By using Boyden chamber assay, the capabilities of the 
cells invasion and migration in vitro were determined. In migration assay, the inserted filter was 
uncoated. For invasion assay, the filter membrane of the inserts was pre coated with Matrigel. 
Bxpc3 and MIAPaca2 showed increased invasion and migration compared to AsPac1. (Fig 16a 
and 16b) 
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Fig.16a Cell invasion assay in pancreatic cancer cell line 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.16b Cell migration assay in pancreatic cancer cell line 
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4.6 Effect of Arsenic on Viability in Pancreatic Cancer Cell Lines 
 
 
To investigate the potential effect of arsenic on survival, three different pancreatic cancer cell 
lines (Bxpc3, Aspc1, and MIAPaca2) were used. In earlier studies we showed mdig was able to 
induce expression in lung cancer cell lines. Similarly, we tried to study the effect of arsenic on 
cell viability in human pancreatic cancer cell line. We treated each of the cell line with arsenic (1, 
5 and 10µM) for 12 and 24 hours led to marked dose-dependent decrease of cell viability as 
determined using crystal violet exclusion. As shown in figure (Fig 17a and 17b) arsenic induced  
a decrease in cell number in dose and time dependent manner. The viable cell count was least at 
higher arsenic concentration. 
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Fig 17b. Cell viability of Bxpc3, Aspc1, MIAPaca2 cells after 12 and 24 hours of arsenic 
treatment. 
 
 
 
 
4.7 Correlation Between Exon Specific Mdig Expression and Overall Survival in Pancreatic 
Cancer Patients. Our earlier studies suggested that increased expression of mdig predicts poorer 
overall survival of breast cancer and lung cancer patients. Studies by other groups also indicated 
poorer survival of the hepatocellular carcinoma with higher level of mdig [105]. To reveal the 
potential prognostic value of mdig expression for the pancreatic cancer patients, we used R2 
genomics visualization tool in a Mixed Tumor Pancreas (Exon) dataset to investigate the changes 
in the patient survival rate with respect to individual mdig exon that was detected by 19 probes 
provided by Affymetrix (Fig 18). Kaplan-meier survival graphs were generated from this data set 
and were compared based on their survival outcomes. Among these 19 survival analysis based  
on the individual probes for different exons, 15 probe sets indicated a poorer survival of the 
patients with higher mdig expression. However, 4 probes, probe sets 8089044, 8089049, 
8089056, and 8089058, which correspond to exon 2, alternative exon 5, and exon 10, predicted 
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better survival of the patients with higher mdig expression (Fig. 19). Since missing exon 2 and 
inclusion of an alternative exon 5 had been found in an alternatively spliced mdig mRNA we 
identified previously, the survival profiles of the different mdig exons suggested an unique or 
opposite role of the alternatively spliced mdig relative to the full length mdig in the pathogenesis 
of the pancreatic cancer. 
 
 
 
hg18:chr3 
 
 
 
 
 
 
 
 
 
Fig 18. The levels of mdig expression predict survival of the patients with pancreatic cancer. 
Diagram of mdig gene structure and the positions of the probe detected. 
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Fig 19. The levels of mdig expression predict survival of the patients with pancreatic cancer. 
Kaplan-Meier survival analysis of the selected probe sets as indicated in the R2: Genomics 
Analysis and Visualization Platform database. 
 
 
 
4.8 Heat map analysis 
 
Heat map clustering of 90 pancreatic cancer patients is presented in (Fig 20.) Along the X-axis 
probe Id’s for MINA/ mdig which overlaps the exonic sequence for mdig is presented. Patient 
samples which are marked red indicate dead and samples which are marked green are alive. 
Complete   patient   information   is   available   in (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). 
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Interestingly, majority of patients who died with pancreatic cancer had high level mdig 
expression. Hence it suggests that mdig contributes to pathogenesis of pancreatic cancer. In all 
Heat map clustering doesn’t provides significant information with respect to exon specific mdig 
expression and overall survival of pancreatic cancer patients. 
 
 
 
 
 
Fig 20. Heat map clustering of pancreatic cancer patient samples. 
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X axis represents probe sets which lies in mdig regions. Y axis represents pancreatic cancer 
patient information. Green indicates (<0) low expression of mdig and red indicates (>0) high 
expression of mdig. The mdig probe Id’s marked RED indicates poor survival rate and BLUE 
indicates better survival rate 
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4. Discussion 
 
There has been a decline in the death rate for the cancers in lung, colorectal, breast, and 
prostate, since 2003. In contrast, the death rate of pancreatic cancer was increasing in the same 
time period. The five year survival rate of pancreatic cancer is only about 6% since 1970s [106]. 
We and others had shown an increased expression of mdig in a number of human cancers, 
including lung cancer, colon cancer, and breast cancer, which implies important contribution of 
mdig towards the pathogenesis of human cancers [53].   However, there are no reports   studying 
the relationship of mdig expression and the clinicopathological features and/or prognosis of the 
 
pancreatic cancer. In the current study, we provide evidence showing that high level of mdig 
expression was a salient feature in human pancreatic cancer cell lines and tissue. By western blot 
analysis, we observed that all the three pancreatic cancer cell lines, BxPc3, Aspc1 and 
MIAPaca2, expressed high level of mdig protein, although there was a slight difference in the 
expression levels of mdig among these three cell lines studied. Bxpc3 and MIAPaca2 showed 
high mdig expression levels compared to AsPc1. The RT-PCR analysis showed mdig mRNA 
expression in all three cell lines. Interestingly, we were able to detect some strong bands of mdig 
mRNAs resulted from alternative splicing. The alternatively spliced mdig mRNAs might have 
distinctive prognostic values against the normally spliced mdig mRNA on the overall survival of 
the pancreatic cancer patients. 
Cell migration is an important component in the spread of pancreatic adenocarcinoma (PA). 
Therefore we tried to study cell migration property in PA cell lines. In trans well migration assay 
Bxpc3 cells had 2.5-fold greater motility than Aspc1 cells. MIApaca2 cell lines had better 
motility than Aspc1 but less than Bxpc3.Another important phenotype of PA cells is its invasive 
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properties, as pancreatic cancer is highly aggressive and invasive by nature, with almost all 
patients presenting with metastasis at the time of diagnosis. Indeed, the presence of metastases is 
thought to be responsible for the poor prognosis of this disease[107]. Therefore we also tried to 
study the difference in cell invasion property in PA cell lines. Bxpc3 cells had 1 fold greater 
invasive property than Aspc1 cells. MIApaca2 cell lines had better invasive ability than Aspc1 
but less than Bxpc3. 
Despite extensive studies, the etiology and mechanisms of the pancreatic cancer are still 
elusive. Some epidemiologic studies suggested a higher incidence rate of pancreatic cancer 
among  African  Americans  than  Whites.  Several  heritable,  germline  mutations  in   p16 
and/or BRCA2 may be associated with the development of pancreatic cancer [4]. It was 
estimated that 95% of pancreatic carcinoma showed inactivation of p16 tumor suppressor [97]. 
P16 is located on chromosome 9, where it encodes a protein that inhibits entry into the S phase   
of the cell cycle by inhibiting cyclin-dependent kinase (CDK) 4/6-dependent phosphorylation of 
retinoblastoma (RB) protein. Inactivation of p16 leads to an uncontrolled cell growth due to a  
fast cell cycle transition [98]. Intragenic mutation, loss of heterozygosity (LOH), homozygous 
deletion, and promoter hypermethylation, may be responsible for p16 inactivation. In addition to 
p16 inactivation, about 50% to75% of pancreatic cancer show dysfunction of p53, one of the 
most important tumor suppressors [99]. As a transcription factor whose gene is located on 17 
chromosomes, p53 regulates a variety of signaling pathways linked to cell cycle arrest, apoptosis, 
and DNA repair. Accordingly, functional inhibition of p53 will lead to loss of cell cycle “check- 
point” [98, 100]. 
Mutations in K-ras gene were frequently observed in a number of human cancers. This 
mutation was also found in almost all resected cases of pancreatic cancer [95]. It was believed 
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that K-ras mutation occurs in the early stage of cancer development [92]. Because of the 
proximity of K-ras gene with other ras family of GTP-binding proteins on chromosome 12, 
genetic abnormality of K-ras gene may be additionally associated with the functional disruption 
of other GTP-binding proteins critical for cell growth, differentiation and survival. 
Chronic pancreatitis of various types was considered as a contributing factor for about 
3%–4% of pancreatic cancer. Apart from germline mutations or pancreatitis, other major risk 
factors associated with pancreatic cancer include cigarette smoking, obesity, diabetes, cirrhosis  
of the liver, etc.. Earlier studies suggested an approximately 40% increased hazard for death of 
the pancreatic cancer patients who smoked cigarettes compared with those who never smoked, 
and risk tends to increase according to frequency or duration of smoking [5]. Dietary studies 
have shown a fairly steady pattern of increase hazard with meat or cholesterol intake and 
decreased risk with fruit or vegetable consumption, although causal inferences regarding these 
associations are still uncertain [6]. 
5. Conclusion 
 
In the current report, we provided evidence showing association of mdig expression and 
the pathogenesis of the pancreatic cancer. Previous studies suggested that increased expression  
of mdig predicts poor survival of the patients with breast cancer, lung cancer and hepatocellular 
carcinoma [105, 108, 109] . By using R2 genomics visualization tool, the probe-exon-based 
analysis also suggested an inverse relationship between the levels of mdig expression and the 
survival of the pancreatic cancer patients. However, 4 out of 19 probes showed that increased 
mdig expression, in fact, predicts a better overall survival of the pancreatic cancer patients,  
which most likely indicated a different or opposite function of the alternatively spliced mdig 
mRNAs. 
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6. Future direction 
 
It remains to be further investigated on how different isoforms of mdig resulted from the 
normal and alternative splicing affect the initiation, progression and pathogenesis of the 
pancreatic cancer. It will also be important to determine whether mdig can serve as a biomarker 
for diagnosis, prognosis and molecular targeting therapy for pancreatic cancer. 
43 
 
 
 
 
Bibliography 
 
 
 
1. Hong, S.M., et al., Molecular signatures of pancreatic cancer. Arch Pathol Lab Med, 
2011. 135(6): p. 716-27. 
2. <Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, 
Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer 
Statistics Review, 1975-2014, National Cancer Institute. Bethesda..pdf>. 
3. Ferrone, C.R., et al., Pancreatic ductal adenocarcinoma: Long-term survival does not 
equal cure. Surgery, 2012. 152(3 0 1): p. S43-9. 
4. Hruban, R.H., et al., Familial pancreatic cancer. Ann Oncol, 1999. 10 Suppl 4: p. 69-73. 
 
5. Yuan, C., et al., Cigarette Smoking and Pancreatic Cancer Survival. Journal of Clinical 
Oncology. 0(0): p. JCO.2016.71.2026. 
6. Risch, H.A., Etiology of pancreatic cancer, with a hypothesis concerning the role of N- 
nitroso compounds and excess gastric acidity. J Natl Cancer Inst, 2003. 95(13): p. 948-60. 
7. Yadav, D. and A.B. Lowenfels, The Epidemiology of Pancreatitis and Pancreatic Cancer. 
 
Gastroenterology, 2013. 144(6): p. 1252-61. 
 
8. Amaral, A.F.S., et al., Pancreatic cancer risk and levels of trace elements. Gut, 2012. 
 
61(11): p. 1583-8. 
 
9. Clapp, R.W., M.M. Jacobs, and E.L. Loechler, Environmental and Occupational Causes 
of Cancer New Evidence, 2005–2007. Rev Environ Health, 2008. 23(1): p. 1-37. 
44 
 
 
10. Parsa, N., Environmental Factors Inducing Human Cancers. Iran J Public Health, 2012. 
 
41(11): p. 1-9. 
 
11. Konner, J. and E. O'Reilly, Pancreatic cancer: epidemiology, genetics, and approaches 
to screening. Oncology (Williston Park), 2002. 16(12): p. 1615-22, 1631-2; discussion 
1632-3, 1637-8. 
12. Ojajarvi, I.A., et al., Occupational exposures and pancreatic cancer: a meta-analysis. 
 
Occup Environ Med, 2000. 57(5): p. 316-24. 
 
13. Andreotti, G. and D.T. Silverman, Occupational risk factors and pancreatic cancer: a 
review of recent findings. Mol Carcinog, 2012. 51(1): p. 98-108. 
14. Lowenfels, A.B. and P. Maisonneuve, Epidemiology and risk factors for pancreatic 
cancer. Best Pract Res Clin Gastroenterol, 2006. 20(2): p. 197-209. 
15. Wogan, G.N., et al., Environmental and chemical carcinogenesis. Semin Cancer Biol, 
2004. 14(6): p. 473-86. 
16. Antwi, S.O., et al., Exposure to environmental chemicals and heavy metals, and risk of 
pancreatic cancer. Cancer Causes Control, 2015. 26(11): p. 1583-91. 
17. Santibanez, M., et al., Occupational exposures and risk of pancreatic cancer. Eur J 
Epidemiol, 2010. 25(10): p. 721-30. 
18. Alguacil, J., et al., Occupational exposure to dyes, metals, polycyclic aromatic 
hydrocarbons and other agents and K-ras activation in human exocrine pancreatic 
cancer. Int J Cancer, 2003. 107(4): p. 635-41. 
19. Andreotti, G., et al., Agricultural pesticide use and pancreatic cancer risk in the 
Agricultural Health Study Cohort. Int J Cancer, 2009. 124(10): p. 2495-500. 
45 
 
 
20. Partanen, T., et al., Pancreatic cancer in industrial branches and occupations in Finland. 
 
Am J Ind Med, 1994. 25(6): p. 851-66. 
 
21. Ji, B.T., et al., Occupational exposure to pesticides and pancreatic cancer. Am J Ind Med, 
2001. 39(1): p. 92-9. 
22. Fritschi, L., et al., Occupational exposure to N-nitrosamines and pesticides and risk of 
pancreatic cancer. Occup Environ Med, 2015. 72(9): p. 678-83. 
23. Burmeister, L.F., Cancer in Iowa farmers: recent results. Am J Ind Med, 1990. 18(3): p. 
 
295-301. 
 
24. Neuberger, J.S., et al., Cancer cluster investigations: use of a hybrid approach in a rural 
county. J Public Health Manag Pract, 2004. 10(6): p. 524-32. 
25. Longnecker, D.S., Environmental factors and diseases of the pancreas. Environ Health 
Perspect, 1977. 20: p. 105-12. 
26. Iodice, S., et al., Tobacco and the risk of pancreatic cancer: a review and meta-analysis. 
 
Langenbeck's Archives of Surgery, 2008. 393(4): p. 535-545. 
 
27. Yuan, C., et al., Cigarette Smoking and Pancreatic Cancer Survival. Journal of Clinical 
Oncology, 2017. 35(16): p. 1822-1828. 
28. Lynch, S.M., et al., Cigarette Smoking and Pancreatic Cancer: A Pooled Analysis From 
the Pancreatic Cancer Cohort Consortium. American Journal of Epidemiology, 2009. 
170(4): p. 403-413. 
29. Glade, M.J., Food, nutrition, and the prevention of cancer: a global perspective. 
 
American Institute for Cancer Research/World Cancer Research Fund, American 
Institute for Cancer Research, 1997. Nutrition, 1999. 15(6): p. 523-6. 
46 
 
 
30. Michaud, D.S., et al., Coffee and Alcohol Consumption and the Risk of Pancreatic 
Cancer in Two Prospective United States Cohorts. Cancer Epidemiology Biomarkers 
&amp; Prevention, 2001. 10(5): p. 429-437. 
31. Jemal, A., et al., Cancer statistics, 2010. CA Cancer J Clin, 2010. 60(5): p. 277-300. 
 
32. Ferlay, J., D.M. Parkin, and E. Steliarova-Foucher, Estimates of cancer incidence and 
mortality in Europe in 2008. Eur J Cancer, 2010. 46(4): p. 765-81. 
33. Chen, W., et al., The incidences and mortalities of major cancers in China, 2009. Chin J 
Cancer, 2013. 32(3): p. 106-12. 
34. Baxter, N.N., B.A. Whitson, and T.M. Tuttle, Trends in the treatment and outcome of 
pancreatic cancer in the United States. Ann Surg Oncol, 2007. 14(4): p. 1320-6. 
35. Zell, J.A., et al., Race, socioeconomic status, treatment, and survival time among 
pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev, 2007. 16(3): 
p. 546-52. 
36. Lau, M.K., J.A. Davila, and Y.H. Shaib, Incidence and survival of pancreatic head and 
body and tail cancers: a population-based study in the United States. Pancreas, 2010. 
39(4): p. 458-62. 
37. Yeo, C.J., et al., Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 
patients. Ann Surg, 1995. 221(6): p. 721-31; discussion 731-3. 
38. Millikan, K.W., et al., Prognostic factors associated with resectable adenocarcinoma of 
the head of the pancreas. Am Surg, 1999. 65(7): p. 618-23; discussion 623-4. 
39. Sohn, T.A., et al., Resected adenocarcinoma of the pancreas-616 patients: results, 
outcomes, and prognostic indicators. J Gastrointest Surg, 2000. 4(6): p. 567-79. 
47 
 
 
40. Benassai, G., et al., Survival after pancreaticoduodenectomy for ductal adenocarcinoma 
of the head of the pancreas. Chir Ital, 2000. 52(3): p. 263-70. 
41. Neoptolemos, J.P., et al., Influence of resection margins on survival for patients with 
pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the 
ESPAC-1 randomized controlled trial. Ann Surg, 2001. 234(6): p. 758-68. 
42. Oettle, H., et al., Adjuvant chemotherapy with gemcitabine vs observation in patients 
undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. 
Jama, 2007. 297(3): p. 267-77. 
43. Klempnauer, J., et al., Surgery for exocrine pancreatic cancer--who are the 5- and 10- 
year survivors? Oncology, 1995. 52(5): p. 353-9. 
44. Neoptolemos, J.P., et al., A randomized trial of chemoradiotherapy and chemotherapy 
after resection of pancreatic cancer. N Engl J Med, 2004. 350(12): p. 1200-10. 
45. Tsuchiya, R., T. Oribe, and T. Noda, Size of the tumor and other factors influencing 
prognosis of carcinoma of the head of the pancreas. Am J Gastroenterol, 1985. 80(6): p. 
459-62. 
46. Gudjonsson, B., Survival statistics gone awry: pancreatic cancer, a case in point. J Clin 
Gastroenterol, 2002. 35(2): p. 180-4. 
47. Beger, H.G., et al., Treatment of pancreatic cancer: challenge of the facts. World J Surg, 
2003. 27(10): p. 1075-84. 
48. Beger, H.G., et al., Pancreatic Cancer – Low Survival Rates. Dtsch Arztebl Int, 2008. 
 
105(14): p. 255-62. 
 
49. Zhang, Y., et al., The Human mineral dust-induced gene, mdig, is a cell growth 
regulating gene associated with lung cancer. Oncogene, 2005. 24(31): p. 4873-82. 
48 
 
 
50. Tsuneoka, M., et al., A novel myc target gene, mina53, that is involved in cell 
proliferation. J Biol Chem, 2002. 277(38): p. 35450-9. 
51. Eilbracht, J., et al., Protein NO52--a constitutive nucleolar component sharing high 
sequence homologies to protein NO66. Eur J Cell Biol, 2005. 84(2-3): p. 279-94. 
52. Yu, M., et al., Paradoxical roles of mineral dust induced gene on cell proliferation and 
migration/invasion. PLoS One, 2014. 9(2): p. e87998. 
53. Thakur, C. and F. Chen, Current understanding of mdig/MINA in human cancers. Genes 
Cancer, 2015. 6(7-8): p. 288-302. 
54. Pan, Q., et al., Deep surveying of alternative splicing complexity in the human 
transcriptome by high-throughput sequencing. Nat Genet, 2008. 40(12): p. 1413-1415. 
55. Wang, E.T., et al., Alternative Isoform Regulation in Human Tissue Transcriptomes. 
 
Nature, 2008. 456(7221): p. 470-6. 
 
56. Oltean, S. and D.O. Bates, Hallmarks of alternative splicing in cancer. Oncogene, 2014. 
 
33(46): p. 5311-5318. 
 
57. Garcia-Blanco, M.A., A.P. Baraniak, and E.L. Lasda, Alternative splicing in disease and 
therapy. Nat Biotechnol, 2004. 22(5): p. 535-46. 
58. Sveen, A., et al., Aberrant RNA splicing in cancer; expression changes and driver 
mutations of splicing factor genes. Oncogene, 2016. 35(19): p. 2413-2427. 
59. Venables, J.P., Aberrant and alternative splicing in cancer. Cancer Res, 2004. 64(21): p. 
 
7647-54. 
 
60. Ghigna, C., C. Valacca, and G. Biamonti, Alternative splicing and tumor progression. 
 
Curr Genomics, 2008. 9(8): p. 556-70. 
49 
 
 
61. David, C.J. and J.L. Manley, Alternative pre-mRNA splicing regulation in cancer: 
pathways and programs unhinged. Genes Dev, 2010. 24(21): p. 2343-64. 
62. Venables, J.P., et al., Cancer-associated regulation of alternative splicing. Nat Struct 
Mol Biol, 2009. 16(6): p. 670-6. 
63. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 57-70. 
 
64. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 
 
144(5): p. 646-74. 
 
65. Kelemen, O., et al., Function of alternative splicing. Gene, 2013. 514(1): p. 1-30. 
 
66. Ladomery, M., Aberrant alternative splicing is another hallmark of cancer. Int J Cell 
Biol, 2013. 2013: p. 463786. 
67. Ladomery, M.R., S.J. Harper, and D.O. Bates, Alternative splicing in angiogenesis: the 
vascular endothelial growth factor paradigm. Cancer Lett, 2007. 249(2): p. 133-42. 
68. Bauman, J.A., et al., Anti-tumor activity of splice-switching oligonucleotides. Nucleic 
Acids Res, 2010. 38(22): p. 8348-56. 
69. Boise, L.H., et al., bcl-x, a bcl-2-related gene that functions as a dominant regulator of 
apoptotic cell death. Cell, 1993. 74(4): p. 597-608. 
70. Matos, P. and P. Jordan, Increased Rac1b expression sustains colorectal tumor cell 
survival. Mol Cancer Res, 2008. 6(7): p. 1178-84. 
71. Zhou, C., et al., The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis. 
 
Oncogene, 2013. 32(7): p. 903-9. 
 
72. Venables, J.P., Unbalanced alternative splicing and its significance in cancer. Bioessays, 
2006. 28(4): p. 378-86. 
50 
 
 
73. Radisky, D.C., et al., Rac1b and reactive oxygen species mediate MMP-3-induced EMT 
and genomic instability. Nature, 2005. 436(7047): p. 123-7. 
74. Surget, S., M.P. Khoury, and J.C. Bourdon, Uncovering the role of p53 splice variants in 
human malignancy: a clinical perspective. Onco Targets Ther, 2013. 7: p. 57-68. 
75. Hirschi, B. and F.T. Kolligs, Alternative splicing of BRAF transcripts and 
characterization of C-terminally truncated B-Raf isoforms in colorectal cancer. Int J 
Cancer, 2013. 133(3): p. 590-6. 
76. Fackenthal, J.D. and L.A. Godley, Aberrant RNA splicing and its functional 
consequences in cancer cells. Dis Model Mech, 2008. 1(1): p. 37-42. 
77. Pajares, M.J., et al., Alternative splicing: an emerging topic in molecular and clinical 
oncology. Lancet Oncol, 2007. 8(4): p. 349-57. 
78. Skotheim, R.I. and M. Nees, Alternative splicing in cancer: noise, functional, or 
systematic? Int J Biochem Cell Biol, 2007. 39(7-8): p. 1432-49. 
79. Zhang, J. and J.L. Manley, Misregulation of pre-mRNA alternative splicing in cancer. 
 
Cancer Discov, 2013. 3(11): p. 1228-37. 
 
80. Liu, J., et al., Genome and transcriptome sequencing of lung cancers reveal diverse 
mutational and splicing events. Genome Res, 2012. 22(12): p. 2315-27. 
81. van Doorn, R., et al., A novel splice variant of the Fas gene in patients with cutaneous T- 
cell lymphoma. Cancer Res, 2002. 62(19): p. 5389-92. 
82. Feng, S., et al., Fibroblast growth factor receptor 2 limits and receptor 1 accelerates 
tumorigenicity of prostate epithelial cells. Cancer Res, 1997. 57(23): p. 5369-78. 
83. Shehadeh, L.A., et al., SRRM2, a potential blood biomarker revealing high alternative 
splicing in Parkinson's disease. PLoS One, 2010. 5(2): p. e9104. 
51 
 
 
84. Johnston, J.J., et al., Massively parallel sequencing of exons on the X chromosome 
identifies RBM10 as the gene that causes a syndromic form of cleft palate. Am J Hum 
Genet, 2010. 86(5): p. 743-8. 
85. Thomas, M., et al., The truncated splice variant of peroxisome proliferator-activated 
receptor alpha, PPARalpha-tr, autonomously regulates proliferative and pro- 
inflammatory genes. BMC Cancer, 2015. 15: p. 488. 
86. Astrof, S. and R.O. Hynes, Fibronectins in vascular morphogenesis. Angiogenesis, 2009. 
 
12(2): p. 165-75. 
 
87. Lee, T.K., et al., An N-terminal truncated carboxypeptidase E splice isoform induces 
tumor growth and is a biomarker for predicting future metastasis in human cancers. J 
Clin Invest, 2011. 121(3): p. 880-92. 
88. Rossi, D., et al., Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: 
association with progression and fludarabine-refractoriness. Blood, 2011. 118(26): p. 
6904-8. 
89. Brat, D.J., et al., Progression of pancreatic intraductal neoplasias to infiltrating 
adenocarcinoma of the pancreas. Am J Surg Pathol, 1998. 22(2): p. 163-9. 
90. Morris, J.P., S.C. Wang, and M. Hebrok, KRAS, Hedgehog, Wnt and the twisted 
developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer, 2010. 
10(10): p. 683-695. 
91. Hansel, D.E., S.E. Kern, and R.H. Hruban, Molecular pathogenesis of pancreatic cancer. 
 
Annu Rev Genomics Hum Genet, 2003. 4: p. 237-56. 
 
92. Deramaudt, T. and A.K. Rustgi, Mutant KRAS in the initiation of pancreatic cancer. 
 
Biochim Biophys Acta, 2005. 1756(2): p. 97-101. 
52 
 
 
93. Hruban, R.H., et al., Progression model for pancreatic cancer. Clin Cancer Res, 2000. 
 
6(8): p. 2969-72. 
 
94. Abramson, M.A., et al., The Molecular Biology of Pancreatic Cancer. Gastrointest 
Cancer Res, 2007. 1(4 Suppl 2): p. S7-s12. 
95. Sakorafas, G.H., A.G. Tsiotou, and G.G. Tsiotos, Molecular biology of pancreatic cancer; 
oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical 
perspective. Cancer Treat Rev, 2000. 26(1): p. 29-52. 
96. Furukawa, T., M. Sunamura, and A. Horii, Molecular mechanisms of pancreatic 
carcinogenesis. Cancer Sci, 2006. 97(1): p. 1-7. 
97. Li, D., et al., Pancreatic cancer. Lancet, 2004. 363(9414): p. 1049-57. 
 
98. Sirivatanauksorn, V., Y. Sirivatanauksorn, and N.R. Lemoine, Molecular pattern of 
ductal pancreatic cancer. Langenbecks Arch Surg, 1998. 383(2): p. 105-15. 
99. Goggins, M., Molecular markers of early pancreatic cancer. J Clin Oncol, 2005. 23(20): 
p. 4524-31. 
100. Rivlin, N., et al., Mutations in the p53 Tumor Suppressor Gene: Important Milestones at 
the Various Steps of Tumorigenesis. Genes Cancer, 2011. 2(4): p. 466-74. 
101. Xiong, H.Q., Molecular targeting therapy for pancreatic cancer. Cancer Chemother 
Pharmacol, 2004. 54 Suppl 1: p. S69-77. 
102. Mimeault, M., et al., Recent advances on the molecular mechanisms involved in 
pancreatic cancer progression and therapies. Pancreas, 2005. 31(4): p. 301-16. 
103. Reddy, S.A., Signaling pathways in pancreatic cancer. Cancer J, 2001. 7(4): p. 274-86. 
53 
 
 
104. McCleary-Wheeler, A.L., R. McWilliams, and M.E. Fernandez-Zapico, Aberrant 
signaling pathways in pancreatic cancer: A two compartment view. Mol Carcinog, 2012. 
51(1): p. 25-39. 
105. Huo, Q., et al., Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer 
progression through regulating H3K9me3/p21 activity. Cell Death Dis, 2017. 8(5): p. 
e2766. 
106. Shin, E.J. and M.I. Canto, Pancreatic Cancer Screening. Gastroenterol Clin North Am, 
2012. 41(1): p. 143-57. 
107. Deer, E.L., et al., Phenotype and Genotype of Pancreatic Cancer Cell Lines. Pancreas, 
2010. 39(4): p. 425-35. 
108. Thakur, C., et al., Increased expression of mdig predicts poorer survival of the breast 
cancer patients. Gene, 2014. 535(2): p. 218-24. 
109. Chen, B., et al., Mdig de-represses H19 large intergenic non-coding RNA (lincRNA) by 
down-regulating H3K9me3 and heterochromatin. Oncotarget, 2013. 4(9): p. 1427-37. 
54 
 
 
ABSTRACT 
 
PATHOLOGICAL AND PROGNOSTIC ROLE OF MDIG IN PANCREATIC CACER 
 
By 
 
SRINIVAS ASHOK KUMAR 
JULY 2017 
Advisor: Dr. Fei Chen 
 
Major: Pharmaceutical Sciences 
 
Degree: Master of Science 
 
 
 
Pancreatic cancer is a highly aggressive malignant disease having very limited therapeutic 
options that ultimately results in its poor prognosis. It is still elusive on the etiology and 
tumorigenic mechanisms of pancreatic cancer. In the present report, we provide evidence 
showing involvement of the mineral dust-induced gene (mdig) in the pathogenesis and prognosis 
of the pancreatic cancer. Using immunohistochemistry approach on human pancreatic cancer 
tissue microarray, we found differential expression of mdig in pancreatic adenocarcinoma and 
normal pancreas. Based on the staining intensities of mdig in these tissue samples, we found that 
12% of the cancer tissues were strongly positive for mdig, 39% and 31% were moderately and 
weakly positive respectively. Several alternatively spliced mdig mRNAs were detected in the 
selected pancreatic cancer cell line. Through R2 platform for the patient survival analysis 
(http://r2.amc.nl), we found that enrichment of some specific exon of mdig predicates different 
survival rate of the pancreatic cancer patients. In summary, our findings may help in assessing 
the role of mdig in the pathogenesis of the pancreatic cancer and the prognosis of the pancreatic 
cancer patients. 
55 
 
 
 
 
 
Keywords: Pancreatic cancer, mdig, alternative splicing, immunohistochemistry, survival rate. 
56 
 
 
AUTOBIOGRAPHICAL STATEMENT 
 
 
SRINIVAS ASHOK KUMAR 
 
 
 
 
 
Srinivas Ashok Kumar obtained his Bachelors in pharmacy from Pune University, 
India in 2014. He worked as Drug Safety Associate in Tata Consultancy limited 
from 2014 to 2015. He joined Wayne State University, Department of 
Pharmaceutical Science to purse his studies as a Master’s student. He joined Dr. 
Fei Chen’s lab in December 2015 as a rotational student. From January he started 
working in his lab and learned many technique. His main project focused on 
Pathological and Prognostic Role of Mdig in Pancreatic Cancer. During his  
research in Wayne State University, Srinivas earned Wayne State Graduate 
Scholarship for winter 2017. 
